The Re-emergence of Gemtuzumab Ozogamicin for AML
In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.
Chimera Virus May Be a New Tool for Combating Lymphomas
Researchers have created a chimera virus that they believe may have the ability to disable certain lymphomas, paving the way for new treatment options.
New Study Offers Insights into Tyrosine Kinase Inhibition in AML Patients
A study by German investigators is elucidating the role of tyrosine kinase inhibitors in targeting FLT3 in acute myeloid leukemia.
Triple Drug Approach May Halt Acute Lymphoblastic Leukemia
Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.
Cord Blood–Derived Immune Cells May Help Combat B-Cell Lymphomas
Natural killer cells derived from donated umbilical cords could be modified to seek and destroy some types of leukemia and lymphoma.
BTK Inhibitor Granted Breakthrough Therapy Designation for Mantle Cell Lymphoma
Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.
Large Genomic Analysis May Lead to New Therapies for Acute Leukemia
A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.
Combating Acute Myeloid Leukemia Relapse Through Stem Cell Biology
Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.
CAR-T Cell Therapy Given Green Light by ODAC for B-Cell Acute Lymphoblastic Leukemia
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
Anti-Leukemic Drug Gemtuzumab Ozogamicin May Benefit Some AML Patients
A new study in JCO suggests that genetic variations within AML patients with CD33 may predict their response to gemtuzumab ozogamicin.